Adriana Plesa

Adriana Plesa

Auto-generated profile, based on publicly available information

Adriana Plesa

Molecular Virology Department, Stefan S. Nicolau Institute of Virology, Bucharest, Romania.

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2011
Verified
Journal Article
Closed access
I(Iulia Virginia Constantin (Iancu)
Iulia Virginia Constantin (Iancu)
Anca BotezatuAnca Botezatu
Anca Botezatu
CGCristina D Goia-Ruşanu
Cristina D Goia-Ruşanu
ASAnca Stănescu
Anca Stănescu
IHIrina Huică
Irina Huică
APAdriana Pleşa
Adriana Pleşa

21 August 2014 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
APAdriana Plesa
Adriana Plesa
GAGabriela Anton
Gabriela Anton
IIIulia V. Iancu
Iulia V. Iancu
CDCarmen Cristina Diaconu
Carmen Cristina Diaconu
IHIrina Huica
Irina Huica
ABAnca Botezatu
Anca Botezatu

2 July 2011
Verified
Journal Article
Closed access
CGCristina D Goia-Ruşanu
Cristina D Goia-Ruşanu
IIIulia V Iancu
Iulia V Iancu
Anca BotezatuAnca Botezatu
Anca Botezatu
DSDemetra Socolov
Demetra Socolov
IHIrina Huică
Irina Huică
GAGabriela Anton
Gabriela Anton

13 July 2016
Verified
Book Chapter
Open access
PDF file
APAdriana Plesa
Adriana Plesa
IIIulia V. Iancu
Iulia V. Iancu
ABAnca Botezatu
Anca Botezatu
IHIrina Huica
Irina Huica
MSMihai Stoian
Mihai Stoian
GAGabriela Anton
Gabriela Anton
The Involvement of Epigenetic Mechanisms in HPV‐Induced Cervical Cancer | InTechOpen, Published on: 2016-07-13. Authors: Adriana Plesa, Iulia V. Iancu, Anca Botezatu, et

30 April 2019 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
APAdriana Plesa
Adriana Plesa
Socolov DemetraSocolov Demetra
Socolov Demetra
IHIrina Huica
Irina Huica
Anca BotezatuAnca Botezatu
Anca Botezatu
I(Iulia Virginia Constantin (Iancu)
Iulia Virginia Constantin (Iancu)
GAGabriela Anton
Gabriela Anton
Introduction: Romania has the highest incidence and mortality rate of cervical cancer in Europe. The objective was to estimate the prevalence of high-risk human papillomavirus (hrHPV) genotypes and to evaluate the role of certain socio-behavioral factors in acquiring viral infection, in a cohort of Romanian women with negative Pap. Methodology: In a prevalence study 611 women (aged 17-58 years) with negative Pap, with no known history of atypical cytology and valid HPV test were included. Each participant completed a questionnaire containing data on socio-behavioral factors. From 344 women aged between 30-58 years, 63 were randomly selected for a second examination (conventional cytology and HPV detection and genotyping) after twelve months. Results: Of the 611 women, 19.80% were HPV positive, 14.73% infected with hrHPV. Differences in the prevalence of hrHPV (17.60% versus 12.50%) as single (13.01% vs 9.01%) and multiple infections (9.71% vs 3.49%) were noted between women under the age of 30 and above. Among socio-behavioral factors, marital status and multiple sexual partners correlate with HPV and hrHPV infection. At follow-up, from 34 HPV negative cases, 10 changed to positive (5 hrHPV), while 2 developed abnormal cytology. Out of the 29 HPV positive cases, 12 cleared the HPV infection and 17 retested positive of which 4 worsened their cytology. Conclusions: In Romania, HPV infection is common in women with negative cytology. HPV genotyping is of epidemiological importance because the distribution of hrHPV types can determine the impact of prophylactic vaccines and the necessity of HPV testing as screening method.

1 December 2003 in International Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
APAdriana Plesa
Adriana Plesa
GAGabriela Anton
Gabriela Anton
CDCarmen Diaconu
Carmen Diaconu
MSMihai Stoian
Mihai Stoian
RRRodica Repanovici
Rodica Repanovici
CCCostin Cernescu
Costin Cernescu
Human papillomavirus (HPV) type 18 is strongly associated with the development of cervical cancer. Studies of a model system with animal papillomaviruses have demonstrated the importance of neutralizing antibodies in preventing papillomavirus-associated disease. The immune response to HPV is poorly understood, and there are non- standardized serological assays to identify HPV infections. In our study, the assessment of antibody responses against HPVs (previously hampered by the lack of viral source) was enabled by the expression of the L1 major capsid viral protein type 18 (HPV18) into L929 murine cells using the pTARGET mammalian expression vector system (MEVS). The cloning was validated by PCR with specific primers for the L1 gene, as well as by enzyme restriction and in situ hybridization. The evidence for the viral cloned gene expression was acquired by RT-PCR. Presence and antigenic properties of the recombinant L1 protein were shown using it as antigen in an indirect enzyme linked immunosorbent assay (ELISA) system. Significantly higher reactivity was noted when the sera samples were from persons infected with HPV18 as compared with the non-infected individuals but a moderately different reactivity was observed when the sera from patients infected with other HPV genotypes were tested. The results showed that the murine transfected cells could be used as antigen in order to detect the presence of the specific antibodies in HPV infected persons.